StemCell Therapy

Indian Biotechnology Market Size, Share & Trends Analysis Report by Type (Healthcare, Crop Production and Agriculture, Industrial, Natural Resources & Environment, and Others) and Forecast 2020-2026

Indian biotechnology market is estimated to grow significantly at a CAGR of 8.1% during the forecast period. The increasing healthcare expenditure and increasing funding in cell-based research in the country are further supporting the biotechnology market in the country. The Government of India has taken some steps to promote cell harvesting techniques in the country and have set up numbers of stem cell banks throughout the country.

Report: http://www.omrglobal.com/requestogy-market

According to International Brand Equity Foundation (IBEF), the Indian healthcare market can increase three-fold to nearly $133.4 billion in 2022. The country is experiencing growth of around 22-25% in medical tourism. Various hospital chains such as Apollo Hospitals and Global Healthcare Enterprise are growing significantly in India due to a huge prevalence of cancer and related diseases. Private hospitals are expanding their business to provide a wide range of diagnostic tests and applications to a massive pool of cancer patients including foreign patients during medical tourism.

Browse for Full Report Description atwww.omrglobal.com/industrogy-market

The Indian biotechnology market is classified on the basis of type.

Based on type, the market is segmented into healthcare, crop production and agriculture, industrial, natural resources & environment, and others. The companies which are contributing to the growth of the Indian biotechnology market include Amgen Inc., Novo Nordisk A/S, CSL Ltd., Bristol-Myers Squibb Co., AstraZeneca PLC, Merck & Co., Inc., Johnson & Johnson Services Inc., and Pfizer Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

Market Segmentation

Indian Biotechnology Market by Type

Company Profiles

Report: http://www.omrglobal.com/report-ogy-market

This email address is being protected from spambots. You need JavaScript enabled to view it.

See the original post here:
Indian Biotechnology Market Market scrutinized in the new analysis - WhaTech

There is a lot of talk about how cell and gene therapy are going to change medicine, so why have only a few of them reached the market?

Over the last decade, only 14 advanced therapy medicinal products (ATMPs) that is, cell and gene therapies have received approval in Europe. With four withdrawals, only 10 of them still have a valid marketing authorization.

That is a stark contrast with the fact that there have been over 500 clinical trials using ATMPs in the EU since 2009. But the reality is that its a bit too soon to be expecting results many of these technologies are brand new and decades-old discoveries are only just reaching the market. For example, the development of Strimvelis, approved in 2016, took more than 20 years. The approval of Chondrocelect in 2009 took nine years since its developer, TiGenix, was founded.

Holoclar initially seemed like an exceptional case: research and development started around 1996 and the first clinical results were published just a year later. But one of its developers, Graziella Pellegrini, reported the product was under development for a total of 25 years. So those excited about CRISPR therapies, based on a gene-editing technology that was only developed in 2012, will still have to wait.

If the time scale wasnt daunting enough, research and development also burns cash quickly.A big chunk of the total money invested goes into meeting the quality, safety, and efficacy standards set by the regulatory authorities. This step seems to represent one of the biggest challenges for developers.

In fact, when regulations for ATMPs were first released in Europe, it appeared that authorities and researchers were on different wavelengths. In 2007, new European Union (EU) regulations on advanced therapies came in, which added more, very frustrating years to the development, said Pellegrini. It seemed that we had to start from scratch.

Thanks to frequent stakeholder consultations, these requirements are constantly being simplified, following the EMAs goal of fostering development and expanding patient access. But even with dynamic regulations, some products may only be authorized at thenational level and not for the whole continent.

For example, there is a dedicated pathway to exceptionally approve and commercialize ATMPs only locally as hospital exemptions. This status includes several limitations: this designation is only for non-routine products and those custom-made for individual patients, and importing or exporting them is illegal which can lead to the dangerous practice of stem cell tourism.

It seems complicated enough to reach the market with a cell or gene therapy, but the struggle isnt over at that point. The EMA can still withdraw a marketing application due to safety issues or if the company doesnt apply (and pay) for a renewal of the marketing authorization after five years.

That was the case of Glybera, the first gene therapy to receive approval in Europe. Its developers decided to not renew its market authorization after the therapys commercial failure in Europe and difficulties reaching the US market. With a very small target market and a price of one million euros, it was the most expensive treatment back in 2012, making it hard to convince governments and private insurance companies to pay for it.

In fact, only one person was treated with Glybera after its approval. Elisabeth Steinhagen-Thiessen, the doctor who prescribed it, had a lengthy fight with the German authorities and the insurance company to make them pay for the treatment. After the withdrawal, three doses left were given to patients for one euro each.

A big challenge for cell and gene therapies is that they often target conditions that affect a very small number of patients. Pharmaceutical companies are not much interested in unprofitable rare disease, commented Pellegrini.

In the case of Strimvelis, there are only about 14 people per year in Europe and 12 in the US diagnosed with its target disease, a rare form of genetic immune deficiency called ADA-SCID. The numbers are better for Holoclar, with around 1,000 people annually in Europe being eligible burn victims who have become blind but whose eyes have not been too extensively destroyed. Still,it is far short of a blockbuster.

There are exceptions, such as Imlygic, a therapy from Amgen approved in 2015 for the treatment of late-stage melanoma, with over 56,000 new cases across the EU each year.

Its fair to say that the majority of withdrawals have been made for business reasons, not safety issues. This highlights the fact that receiving EMA approval does not guarantee commercial viability the product can still be an economic failure.

Clearly, we have a lot of lessons to learn from past failure and success stories. As regulators and insurance companies become more familiar with cell and gene therapies, and developers avoid the mistakes made by others in the past, we can expect a future where cell and gene therapies become commonplace and no longer a futuristic hope.

Cover illustration by Elena Resko, images via Pharma Boardroom and the author. This article was published in April 2018 and has since been updated to reflect the latest EMA approvals.

Read the original here:
Why Are There Only 10 Cell and Gene Therapies in... - Labiotech.eu

The World Organisation for Animal Health (OIE) is examining how misunderstandings surrounding COVID-19 may have compromised animal welfare during the pandemic.

The COVID-19 thematic platform on animal welfare is an initiative of the OIE Collaborating Centre Network for Veterinary Emergencies, or EmVetNet, that tracks how the disease is impacting the welfare of livestock, pets, wildlife, and other animals for the purpose of identifying trends, aiding research, and informing policy.

Since the beginning of the COVID-19 pandemic, efforts are ongoing to understand the potential origin of this virus and whether animals can be infected or spread the disease. At this time, there is no sufficient evidence to suggest that any animal, including pets or livestock, play a role in the transmission of COVID-19. However, misunderstanding has resulted in threats to animal welfare, according to the EmVetNet website.

For instance, measures taken to contain the virus have disrupted many animal-related activities around the world, at places from shelters to zoos to institutes that use laboratory animals. The pandemic will also have a lasting economic impact, which in turn may impact animal ownership and animal care.

The OIE platform draws heavily on the work of Lincoln Memorial University College of Veterinary Medicine along with input from the AVMA, the Federation of Veterinarians of Europe, the International Coalition for Animal Welfare, the Israeli State Veterinary Services, and the Royal Society for the Prevention of Cruelty to Animals in the United Kingdom. Together, these organizations have set up the platform to map the impact of COVID-19 on animal welfare, observe trends, identify lessons, and share solutions and best practices to aid research, assist with policy development, and improve the response to future events, according to the EmVetNet website.

Under the direction of Dr. Gary Vroegindewey, director of the One Health Program at LMUs veterinary college, summer research students and volunteerswith faculty supervisioncollected, analyzed, and provided narratives on a wide range of COVID-19related issues across multiple animal groups. In all, they catalogued over 1,100 animal welfare-related reports and provided 48 report analyses and narratives for the OIE working group.

It is not often a student can say they conducted research for the World Organisation for Animal Health in the midst of a global pandemic that could have a lasting impact on their field of study, said Dr. Stacy Anderson, dean of LMUs veterinary college, in an Aug. 14 report on television station WVLT.

The work of Lincoln Memorial University contributes greatly to our understanding of the impacts of animal welfare during emergencies, said Dr. Paolo Dalla Villa, who chairs the Steering Group of the OIE Collaborating Centre for Animal Welfare in Europe, in the same report. The results of their contributions and the working group will go beyond the current pandemic and provide a framework to integrate animal welfare into future initiatives.

Here is the original post:
OIE tracks COVID-19 threats to animal welfare - American Veterinary Medical Association

How should a veterinarian respond when a client asks about treating a pet dog with a cannabinoid tincture advertised as an analgesic? Is there research supporting that use or underlying any of the claims made for the scores of cannabis and cannabinoid-based products marketed for pets? Does a practitioner who recommends such a product for a patient risk running afoul of the state licensing board, the Food and Drug Administration, or the Drug Enforcement Administration?

These were just some of the thorny issues covered during the first-ever AVMA Cannabis Symposium, held Aug. 20-22 during the AVMA Virtual Convention 2020. Speakers addressed various aspects of cannabis as a veterinary therapeutic, such as regulatory and toxicological concerns, as well as its potential as an analgesic or treatment for osteoarthritis in animal patients. Following are some of the speaker highlights.

Thirty-three states have legalized marijuana for medicinal or recreational use by peopleor both. And yet, none of these laws account for use of cannabis in veterinary medicine. California is the only state to specifically address veterinarians ability to engage with clients, indicating that veterinarians can discuss the use of cannabis for medical purposes with clients without being disciplined by the veterinary medical board solely for having that conversation. By that same statute, veterinarians are prohibited from prescribing, dispensing, or administering any cannabis or cannabis-based products. The statute does not address the therapeutic use of products derived from industrial hemp, which are covered under provisions of the states veterinary practice act applicable to diagnosing, prescribing, or administering a drug for prevention or treatment of an animals condition.

The Food and Drug Administration has approved only one cannabis-derived drug and three synthetic cannabis-related drugs, all for use in human medicine. No other cannabis, cannabis-derived, or cannabidiol product currently available is approved by the agency.

We certainly recognize the potential opportunities that cannabis-derived compounds may offer and acknowledge the significant interest in these possibilities, said symposium speaker Randall Gnatt, a senior regulatory counsel in the Office of Surveillance and Compliance in the FDAs Center for Veterinary Medicine.

Were also aware that some companies are marketing products in ways that violate the federal Food, Drug, and Cosmetic Act and then may put the health and safety of people and animals at risk, he explained. The agency is committed to protecting the public health while also taking steps to improve the efficiency of regulatory pathways for the lawful marketing of appropriate cannabis-derived products.

Gnatt said the FDA is conducting a comprehensive evaluation of CBD and related products with a focus on educating the public about these products, informing the agencys regulatory considerations of these products, and taking action when necessary to protect public health.

We understand theres high demand with consumers seeking out these novel products for a variety of perceived health-related or other reasons. But as the agency has stated before, we are concerned that some people wrongly think that the myriad of CBD products on the market have been evaluated by FDA and determined to be safe, which, as Gnatt explained, isnt the case.

Other than the approved human prescription drug, we know little about the potential effects of sustained or cumulative long-term use of CBD, Gnatt continued. We dont know about coadministration with other medicines or risks to vulnerable human and animal populations. This doesnt mean that we know CBD is categorically unsafe under all circumstances, but given the gaps in our current knowledge and the known risks that have been identified, were not at a point where we can conclude that CBD products are safe for use.

Little is known about the effects of cannabis and CBD on various nonhuman animal species, particularly with regard to the accumulation of residues in the edible tissues of food-producing animals. There is a great need for more rigorous scientific research into both safety and potential therapeutic uses of cannabis-derived products for animals, Gnatt said.

Conflicting federal and state laws either prohibiting or sanctioning medical marijuana or hemp-derived CBD can put veterinarians in a difficult spot. Clients are able to get these products right down the street or through the internet, and theyre looking for advice from their veterinarian, said Jim Penrod, executive director of the American Association of Veterinary State Boards.

Penrod spoke during the cannabis symposium about the varying views among U.S. veterinary licensing boards about the issue. Marijuana was illegal for decades, he explained, adding that the drug was difficult to study given its classification as a Schedule 1 substance. When California legalized medical marijuana in 2006, the state let the genie out of the bottle, as it were, with the decriminalization process quickly outpacing the research.

Because things are progressing so quickly and decisions are being made so quickly Im not going to give you the answers today. Im not going to tell you that, Yes, its fine for you to go talk about cannabis, or Its fine for you to dispense. I dont have those answers, Penrod said.

In 2019, the AAVSB surveyed state veterinary licensing boards about whether it is legal for a veterinarian to discuss cannabis with a client. Penrod said the association recently contacted those boards to determine whether they were still comfortable with the answers they gave in the 2019 survey, and several changed their answers.

Responses varied from one extreme to the other. Six states said veterinarians could lose their license if they even talk about cannabis, four said veterinarians need to adhere to federal law, seven said state boards cant even provide legal advice, seven said they have no formal opinion on the matter, two said veterinarians could talk about cannabis but only if the client starts the conversation, 18 responded that veterinarians could discuss cannabis but could not prescribe or dispense it, and four said veterinarians could discuss the topic.

The position of the AAVSB is that veterinarians should be able to discuss CBD with a client to ensure animal and public protection. That just makes sense, Penrod said. If a client comes in and says, Im going to use CBD on an animal, you should be able to talk to them about it, to warn them about some of the side effects, to watch out for those, to make sure that theyre purchasing a product thats been analyzed and it doesnt contain things like pesticides.

The AAVSB has created a task force to create guidance documents for regulatory boards concerning the issue of cannabis. Because things are changing so quickly, if we drafted regulations or practice law language, it could be out of date as soon as we published it. Guidance is a little more flexible, Penrod said.

Dr. Trina Hazzah is regularly questioned about cannabis use even though there are no cannabis products approved for therapeutic use in animals.

That is, clients frequently ask Dr. Hazzah, a veterinary oncologist working in Los Angeles whose area of interest is complementary and alternative medicine, about incorporating cannabis into their pets treatment protocols.

Dr. Hazzah, a founder and the co-president of the Veterinary Cannabis Society, offered her perspective on the therapeutic use of cannabis-derived products as part of the AVMA Cannabis Symposium.

As Dr. Hazzah explained, cannabis is primarily used with animals as an anti-inflammatory, analgesic, anti-anxiety, or anti-neoplastic. Prior to considering a cannabis product, the patient must first be evaluated to confirm that the animal has a potentially cannabis-responsive condition.

Does the patient have any contraindications or comorbidities that may prevent you from starting cannabis? Are there any potential drug interactions that you should be aware of? Dr. Hazzah asked. The next step is to evaluate the actual product as well as the product safety.

She cited a 2015 study that evaluated 75 edible cannabis products available in various California cities and found that just 7% of the products were accurately labeled for the cannabinoid content. In a follow-up session, Jack Henion, PhD, professor emeritus of toxicology at Cornell University, also conveyed results of a similar study where 12 of 13 animal products had greater THC levels than Canadas acceptable limits.

Its really, really important that clients do their due diligence and ask for a certificate of analysis, said Dr. Hazzah, who discourages clients from treating pets with cannabis products marketed for human illness.

You want to walk them through finding companies that are transparent, that have good customer service, that have up-to-date COAa certificate of analysisconfirming that the product is free of contaminants and that is very specific on what is in the product, she said.

Talk to clients about potential adverse effects and what signs to look for in pets, Dr. Hazzah added.

And then, lastly, you should set really clear expectations with a client, making sure that they know that cannabis is not necessarily a wonder drug, Dr. Hazzah explained.

Dr. Dharati Szymanski, an assistant director in the AVMA Division of Animal and Public Health and organizer of the summit, summarized the event thus: Our members hear varying perspectives from cannabis manufacturers, their state boards, regulatory agencies, colleagues, and, of course, clients. Sometimes it is difficult to see where these perspectives might intersect or how far apart they sit. Practitioners want to have confidence in the safety and efficacy of products. However, when the marketplace has outpaced the evaluation of products, veterinarians need to understand the potential benefits as well as risks surrounding these products for their patients and the liability risks for themselves. There has been much progress in bridging these gaps, but we need more work in areas of research, quality control, and FDA evaluation for veterinarians to have general confidence in available products.

See the rest here:
The hype and hope of veterinary cannabis - avma.org

Backyard poultry and small-scale livestock agriculture are a growing trend in the U.S., even in large cities such as Seattle, Portland, Denver and San Francisco. Residents raising backyard poultry and livestock do so for a variety of reasons such as access to locally sourced food, companionship and sustainability. But how often do these owners seek veterinary care in these urban and peri-urban areas (UPAs)?

A Western Regional team of collaborators, including UC Davis researchers, conducted a survey of veterinary practitioners to better assess their engagement with owners of these animals. They received responses from 880 veterinarians in California, Colorado, Washington and Oregon. Most respondents reported working in companion animal only or companion animal predominant practices. Although most of the veterinarians perceived an increase in backyard poultry and livestock in their practice areas, few were actively treating such animals primarily because of a lack of facilities, interest or experience.

Their findings, published in theJuly 15th issue of theJournal of the American Veterinary Medical Association, indicate an increasing demand for veterinary services for poultry and livestock in peri-urban areas, and a need for ongoing continuing education of practitioners, as well as the animal owners.

This segment of agriculture has been largely overlooked by the veterinary community in North America, said Dr. Alda Pires, University of California cooperative extension specialist in the UC Davis School of Veterinary Medicine and co-principal investigator in the study. Due to the potential for public health issues and the spread of zoonotic disease, veterinary professionals need increased training and better awareness of the health and welfare of these animals.

Dr. Ragan Adams, veterinary extension specialist at Colorado State University and a co-principal investigator emphasized that the animal owners also need better awareness of the importance of regular veterinary care and a willingness to pay for that medical expertise.

Many of these owners are unfamiliar with the responsibilities and challenges of owning poultry and/or livestock, Adams said. County Extension personnel can teach the new animal owners as they have taught youth in 4-H programs for more than 100 years. With enhanced knowledge about animal husbandry, the new owners will understand the importance of seeking veterinary services when their animals show signs of illness.

Disease spread from these peri-urban areas can spell disaster for other animals. For example, the 2015 outbreak of highly pathogenic avian influenza, traced to backyard poultry flocks, had severe economic and trade consequences for the commercial poultry industry. Recent outbreaks of virulent Newcastle disease in California also posed significant threats to commercial poultry flocks and the agricultural economy.

The health and welfare of animals in UPAs are of concern because their owners often lack the knowledge or expertise regarding safe handling and animal husbandry, said Dr.DaleMoore, Washington State University Veterinary Medicine Extension specialist and co-investigator.

A previous surveyfound that the owners want more access to livestock and poultry medicine. This follow-up survey highlights the need for veterinarians, along with extension specialists to work with small-scale poultry owners to improve biosecurity measures, better detect disease and mitigate potential future outbreaks.

The original study ideas for these surveys came from Washington State University Veterinary Medicine Extension (Drs. Dale Moore and Amos Peterson) as part of Petersons Masters Thesis project. The project was then extended to Veterinary Medicine Extension in California (Drs. Pires, Jerome Baron and Beatriz Martinez-Lopez), and at Colorado State University (Dr. Ragan Adams). Extension educators at Oregon State University and the Oregon Veterinary Medical Association helped with contacts in their states.

The increase in popularity of backyard and peri-urban agriculture provides both challenges and opportunities for veterinarians. Providing veterinary service to owners of backyard poultry and livestock, who often view their animals as pets rather than production animals, requires a different approach and some different skills than providing veterinary service to owners of conventional or commercial livestock operations.

Study authors suggest a new model of practice might be envisioned for urban and peri-urban poultry and livestock clientele to ensure the health and welfare of their animals, and to safeguard public health. Specific opportunities for the veterinary profession are to identify local or regional veterinary service needs for these owners, become equipped to address exotic or zoonotic disease detection and husbandry questions, and provide medical care as well as food safety advice.

Read the original post:
Study shows that veterinarians play a role in backyard poultry safety - Jill Lopez

A lot has been said about CBD pet products and their capacity to tame anxiety and other stressors that pets experience. Anecdotal evidence indicates that many pet owners are happy with the cannabis products theyve used on their pets, stating they put their pets at ease when theyre exposed to stressors like fireworks and separation anxiety. Pet owners feel a sense of comfort when using these products, since there are little to no side effects associated with them.

A cannabis symposium hosted by the American Veterinary Medical Association (AVMA)last month delved into the topic of veterinary cannabis, with different experts discussing its pros and cons.

We certainly recognize the potential opportunities that cannabis-derived compounds may offer and acknowledge the significant interest in these possibilities, said Randall Gnatt, a senior regulatory counsel in the Office of Surveillance and Compliance in the FDAs Center for Veterinary Medicine.

RELATED: The Relationship Between CBD And Owning Pets Is Deeper Than You Think

Were also aware that some companies are marketing products in ways that violate the federal Food, Drug, and Cosmetic Act and then may put the health and safety of people and animals at risk.

Waking up to this every morning would surely give you more will to live. Unsplash/jonathan daniels, CC BY-SA

While Gnatt made it clear that CBD is a promising compound for both humans and animals, he also expressed the FDAs concern regarding it, particularly in the way in which the cannabinoid has been advertised by dozens of companies. Other than the approved human prescription drug, we know little about the potential effects of sustained or cumulative long-term use of CBD, he said.

RELATED: Some CBD Pet Products Dont Actually Contain Any CBD

We dont know about coadministration with other medicines or risks to vulnerable human and animal populations. This doesnt mean that we know CBD is categorically unsafe under all circumstances, but given the gaps in our current knowledge and the known risks that have been identified, were not at a point where we can conclude that CBD products are safe for use.

CBD and cannabis remain largely unregulated. While significant steps have been made over the years to validate the medicinal claims of cannabis, much work needs to be done in order to get a full picture of the plant, especially if were giving it to animals who have no say on the matter and who might be better off visiting their veterinarian.

See the original post:
What Pet Owners Should Know About Cannabis And CBD Products - The Fresh Toast

Global Veterinary Medicine Marketexpected to reach around US$ XX Bn by 2027, growing at a CAGR of 6.4% during the forecast period.

The MMR report includes various segments as well as an analysis of the trends and growth factors that are playing a substantial role in the market. These factors the market dynamics involve the drivers, restraints, opportunities, and challenges. Such as, The rise in the occurrence of contagious diseases among animals is driving the market for veterinary drugs. Animals also play a crucial role in research and development in studying drug therapy by performing preclinical trials in animals to develop advance drug and cost-effective veterinary drugs. Moreover, increasing awareness towards livestock and to cure zoonotic and chronic disease drives the market, rapid urbanization and an increase in per capita income drive the market growth.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/54077

However, the discovery of complex diseases and various infections in humans from animals through the consumption of animal products such as bird flu, bird flu, rabies, coronova virus, and others and not giving street animals appropriately treatment restraints the market growth.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Opportunities:

Growing research and development investment to develop more effective drugs Rising meat consumption across the globe and animal-derived product like ghee, milk, butter give a better opportunity.

Global Veterinary Medicine Market: Market Segmentation:

The report covers the brief analytical segments of the veterinary medicine market thereby providing a wider view at the macro as well as micro levels. By route of administration, parenteral is dominating the veterinary medicine market and valued around US$ XX Bn in 2019. Parenteral administration is more preferred over other as it gives rapid onset of action, The better bioavailability, and reliable dosage and it gives fast therapeutic effect with rapid onset of action as it overcomes the first-pass metabolism whereas, several adverse reactions and painful delivery and discomfort are the drawbacks and hinder the growth.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/54077

Pharmacies & drug stores segment is projected to witness the fastest growth during the forecast period. Because of the requirement and urgency in clinical for targeted medicines and to protect from zoonotic diseases and livestock animals.

Global Veterinary medicine market: Regional analysis

North Americas Veterinary medicine market was valued at US$ XX million in 2019 and is expected to reach a value of US$ XX million by 2027, with a CAGR of XX%. The major factors which are driving the growth of the Veterinary medicine market in the regions as it provides good animal welfare policies and its spend huge expenditure on research in veterinary medicine market especially the U.S and Canada. Since, North America is the developed region it consists of advance veterinary hospital and the large healthcare players and hence, take part in growing the economics of the market.

Europe is considered the second most promising market after North America in the Advancement of new techniques and growing healthcare agencies the European market is undertaken by Germany and Frances and so, drives the European market.

Recent Development:

In June 2018, Merck entered into a business with Vinovo B.V a division of Viscon Hatchery Automation. This has aided the company increase its portfolio of poultry vaccines.

The objective of the report is to present a comprehensive analysis of the Global Veterinary Medicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Veterinary Medicine Market dynamics, structure by analyzing the market segments and project the Global Veterinary Medicine Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Veterinary Medicine Market make the report investors guide.Scope of the Global Veterinary Medicine Market:

Global Veterinary Medicine Market, By Product

DrugsAnti-infectivesAnti-inflammatoryParasiticides VaccinesInactivated VaccinesAttenuated VaccinesRecombinant Vaccines Medicated Feed AdditivesAmino acidsAntibioticsGlobal Veterinary Medicine Market, By Route of Administration

Oral Parenteral TopicalGlobal Veterinary Medicine Market, By Application

Companion Animals Livestock AnimalsGlobal Veterinary Medicine Market, By End-User

Veterinary Hospital Veterinary Clinics Pharmacies & Drug StoresGlobal Veterinary Medicine Market, By Region

North America Europe Asia Pacific Middle East and Africa Latin AmericaGlobal Veterinary Medicine Market, key Players

Agrovet Market Animal Health American Veterinary Clinic Animalcare BASF India Ltd Belfarmacom Bimeda Biotex Plus Ltd Boehringer Ingelheim Gmbh Brouwer Cadila Pharmaceuticals Ltd Cargill India Pvt. Ltd Ceva Chemo Argentina Koninklijke DSM N.V Mars Merck & Co. Saudi Pharmaceutical Industries Sauvet Selecta Syntec The British Veterinary Center UCBVET Vetanco Veterinarski Zavod Subotica Vetmedica Wageningen Bioveterinary Research Wilbur-Ellis Zoetis

MAJOR TOC OF THE REPORT

Chapter One: Veterinary Medicine Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Veterinary Medicine Market Competition, by Players

Chapter Four: Global Veterinary Medicine Market Size by Regions

Chapter Five: North America Veterinary Medicine Revenue by Countries

Chapter Six: Europe Veterinary Medicine Revenue by Countries

Chapter Seven: Asia-Pacific Veterinary Medicine Revenue by Countries

Chapter Eight: South America Veterinary Medicine Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Veterinary Medicine by Countries

Chapter Ten: Global Veterinary Medicine Market Segment by Type

Chapter Eleven: Global Veterinary Medicine Market Segment by Application

Chapter Twelve: Global Veterinary Medicine Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Veterinary Medicine Market Report at:https://www.maximizemarketresearch.com/market-report/global-veterinary-medicine-market/54077/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email:sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

See the original post here:
Global Veterinary Medicine Market- Industry Analysis and Forecast (2020-2027) by Product, Route of Administration, Application, End-User and Region....

Gucci, one of 4,000+ pet heroes treated at a PetCure Oncology cancer care center

West Islip, NY, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Advanced radiation therapy for pets with cancer will soon be available in Long Island, New York following the announcement of a new collaboration between PetCure Oncology and the Veterinary Medical Center of Long Island (VMCLI) on Tuesday.

The new service is already accepting referrals from local veterinarians with an opening date less than two weeks away on October 5. Those interested in more information or the advice of a board-certified veterinary radiation oncologist can call 833-PET-HERO, a toll-free number dedicated to supporting pets with cancer and the families who love them.

Located in central Long Island in West Islip, VMCLI is the islands leading veterinary specialty practice and 24/7 emergency center. The addition of radiation oncology, combined with VMCLIs current oncology offerings, provides pet owners in Long Island with access to comprehensive cancer care all under one roof at VMCLI - a first for the island.

We are really proud to bring this level of cancer care to pets in Long Island, said Dr. Robert Composto, DVM, Co-Founder and Director of VMCLI. We are committed to both learning and providing cutting-edge veterinary medicine. Adding radiation oncology and partnering with PetCure keeps VMCLI at the forefront of cancer treatment for pets.

The program will be overseen by Dr. Rick Chetney, a New York native and one of nine board-certified radiation oncologists in the PetCure Oncology national network.

PetCure Oncology is a national brand that develops and manages radiation therapy centers featuring stereotactic radiation (SRS/SRT), the most advanced form of radiation therapy available. Already a proven care option for human cancer patients, SRS/SRT has become increasingly common in the treatment of pets with cancer. PetCure Oncology has supported this process by increasing access to SRS/SRT for pet owners, facilitating innovative clinical trials, and sharing data and research results from over 4,000 treatments to improve the impact of this therapy on survival times and quality of life.

At the most recent meeting of the Veterinary Cancer Society, PetCure Chief Medical Officer Dr. Neal Mauldin presented preliminary outcomes data that suggested SRS/SRT delivered with PetCure-developed treatment protocols is leading to better survival outcomes than other treatment options for at least nine specific tumor types. The list includes some of the most common types of pet cancer, most notably brain tumors, nasal tumors, osteosarcoma, mast cell tumors and melanoma.

Its great news that so many of our pets are still alive and thriving, so the data is still maturing, explained Dr. Mauldin, whose board certifications include radiation oncology, medical oncology and internal medicine. But objective analysis of the preliminary data at this point suggests that stereotactic radiation can be considered a standard of care for the treatment of many tumor types - much like it already is in human cancer treatment.

About PetCure Oncology: PetCure Oncology LLC is a marketing and management services company affiliated with PetCure Radiation Oncology Specialists (PROS), a veterinary healthcare provider with nine board-certified radiation oncologists that have treated more than 4,000 pets with cancer since 2015. Supporting eight treatment centers across the country and counting, PetCure also facilitates innovative telehealth services for both veterinarians and pet owners. For more information, contact a PetCure Pet Advocate at 833-PET-HERO.

Follow this link:
PetCure Oncology and VMCLI Fighting Pet Cancer in Long Island, NY - GlobeNewswire

Friday, September 18, 2020

Did you know that Drew Brees is a professor at the College of Veterinary Medicine? A pet professor that is, or rather pet professors.

The legendary football player is represented in the college in the form of two dogs, a Terrier mix named Drew and an Australian Shepherd border mix named Brees. Brees is owned by Dr. Ellen Lowery, director of the Purdue University Veterinary Hospital, while Drew is owned by Dr. Jim Weisman, assistant dean for student affairs.

As far as the name Drew goes, its basically my admiration for Drew Brees. Im a Boilermaker through and through, Dr. Weisman says. Drew is about nine-years-old and Dr. Weisman describes him as a very self-sustained dog. He enjoys playing fetch by himself by dropping a ball down a flight of stairs and bringing it back up to the top. Dr. Weisman says, for a dog, Drew is rather organized. He has his own toy box that he gets his things out of at the beginning of the day, but always brings them back and puts them away at the end of the day.

As for Brees, Dr. Lowery says, Im not the biggest football fan, but I have so much respect for Drew Brees. She says that Brees is about five-years-old and has a calm demeanor overall, but also is not afraid to act like a watchdog when she needs to. Dr. Lowery explains that when theyre home, She keeps all of the squirrels and chipmunks in line. When Brees is off-duty from her watchdog role, she enjoys being a greeter in the College of Veterinary Medicine. Students may find her in a hallway between classes always happy to be petted. Dr. Lowery says that students and staff love having Brees as a local mascot for the college.

Both of these dogs are involved in the colleges Pet Professor program. Animals in the program are often the pets of staff and faculty and provide a way for students to learn the foundations of conducting physical examinations and giving vaccinations to domestic pets as well as practicing ultrasounds and minor physical therapy techniques. Animals like Drew and Brees get a free examination while students get fun friends to play with and learn from, and who wouldnt want a teammate like Drew Brees!

Writer(s): Jonathan Martz, PVM Communications Intern | pvmnews@purdue.edu

Visit link:
It's Not Far-fetched to Find Drew Brees in the College of Veterinary Medicine - Purdue Veterinary News

Dr. Bell said keeping animals out of the smoke as much as possible is best case, but if they must be outside, pet owners should limit that time if possible.

By Josh Babcock, College of Veterinary Medicine

Until the smoke clears, Washington State University veterinarians say the best thing pet owners can do is keep their animals indoors.

According to an air quality alert issued by the Washington State Department of Ecology, widespread smoke and haze is expected to cause unhealthy air quality throughout the week.

I would take the same precautions for pets that you would take for you and your family, said Dr. Jessica Bell, a small animal veterinarian at WSUs College of Veterinary Medicine.

Dr. Bell said keeping animals out of the smoke as much as possible is best case, but if they must be outside, pet owners should limit that time if possible.

Heavy breathing is worse for animals in smoky conditions and any strenuous exercise should be avoided, she said.

Water bowls for animals can pick up pollutants and should be changed and monitored more often, especially those outdoors, Bell said. If their water is contaminated with whats in the air, they may hesitate to drink it next time.

Bell recommends monitoring elderly pets and pets with respiratory conditions when smoke is lingering.

Look for any discomfort, coughing, heavy breathing; sometimes conditions like these aggravate other problems, she said.

Bell said with so many particles in the air, now is the worst time for a dog to have its head out of the window of a vehicle, noting smoke irritates the face and eyes of animals.

If animals are showing signs of discomfort, it is best to consult your regular veterinarian.

Original post:
Veterinarians: Keep your pets out of the smoke - WSU News

As a second-generation veterinarian, Michael Blackwell, director of the Program for Pet Health Equity in the University of Tennessee, Knoxvilles College of Social Work, has witnessed the American publics behavior toward companion animals shift to treating them not just as pets but as family members.

With two-thirds of American households having nonhuman family members, the need for affordable veterinary care is more important than ever. With the 2008 recession, Blackwell saw firsthand a surge of families struggling to pay for services, specifically veterinary care, and he recognized the need to improve access to this care. The COVID-19 pandemic has significantly increased the number of families needing support.

We have tens of millions of individuals called pets embedded in communities across the country, and they dont have adequate access to care, Blackwell stated. That threatens not only the familys health but the communitys health and the nations well-being.

In 2017, Blackwell began leading an interdisciplinary team at UT composed of members from the College of Social Work, the Haslam College of Business, the College of Veterinary Medicine, and the Department of Public Health in the College of Education, Health, and Human Sciences to establish the program, which works to connect underserved individuals with veterinary service providers. In 2018 it received $2.8 million from Maddies Fund to research and develop AlignCare.

Were putting in place a system that will be in part a safety net but also a structured approach so we can more efficiently and effectively reach underserved families, Blackwell said.

As the programs director, Blackwell works with consultants and volunteers across the country to coordinate and reiterate its vision.

My vision is one day, any family that needs to see a doctor, whether its the human or the nonhuman member, will be able to see a doctor and get needed care, Blackwell said.

Blackwell integrates UT graduate students in business, public health, and social work into the program, providing eye-opening exposure to the differences between veterinary medicine and the health care industry and to the economic impacts of delivering health care.

In regard to his students, Blackwell said, Theyve come to appreciate how connected things are in this world. Students are regularly appreciating the humananimal bond, and the organizations providing family support services need to change their programs to see the holistic family.

Currently the program is operating in four citiesKnoxville; Asheville, North Carolina; Phoenix, Arizona; and Long Island, New York. These cities had interested partners who were on board and ready to start building this program within the communities.

Recently UT received $600,000 from the Dave & Cheryl Duffield Foundation to expand these services to Las Vegas and Reno, Nevada. Other U.S. communities will be added as funding permits.

Blackwell attributes much of the programs success to its past and current team members as well as the many partners, consultants, and volunteers who have stepped up.

The people who need assistance in our country are actually our neighborsand they are primarily the working poor, who, ironically, work in service industries, Blackwell said. As a nation we are fortunate we still have so many compassionate people in our midst.

Blackwell is the 2020 recipient of the Avanzino Leadership Award, recognizing his outstanding leadership and purposeful dedication to the humananimal bond.

To learn more about the Program for Pet Health Equity, visit pphe.utk.edu.

CONTACT

Heather Peters (heatherpeters@utk.edu)

Diane Carr Tolhurst (dcarr9@utk.edu)

Read more:
UT Receives Funding to Address Socioeconomic Barriers to Veterinary Care - Tennessee Today

As Americans begin pulling up their sleeves for an annual flu vaccine, researchers at the University of WisconsinMadison have provided new insights into an alternative vaccine approach that provides broader protection against seasonal influenza.

In a study published in Cell Reports Medicine today (Sept. 22), scientists describe a T-cell-based vaccine strategy that is effective against multiple strains of influenza virus. The experimental vaccine, administered through the nose, delivered long-lasting, multi-pronged protection in the lungs of mice by rallying T-cells, specialist white blood cells that quickly eliminate viral invaders through an immune response.

This three-dimensional, semi-transparent rendering of a whole influenza virus shows both the clover-like surface proteins on the outside of the virus, as well as the internal ribonucleoproteins on the inside. Existing influenza vaccines introduce proteins found on the surface of flu viruses to help induce immune protection. A new study by researchers at the UW School of Veterinary Medicine uses an internal nucleoprotein to stimulate the immune system in an effort to create a universal flu vaccine. Centers for Disease Control and Prevention

The research suggests a potential strategy for developing a universal flu vaccine, so you dont have to make a new vaccine every year, explains Marulasiddappa Suresh, a professor of immunology in the School of Veterinary Medicine who led the research. The findings also aid understanding of how to induce and maintain T-cell immunity in the respiratory tract, a knowledge gap that has constrained the development of immunization strategies. The researchers believe the same approach can be applied to several other respiratory pathogens, including the novel coronavirus that causes COVID-19.

We dont currently have any vaccine for humans on the market that can be given into the mucosa and stimulate T-cell immunity like this, says Suresh, a veterinarian with specialty training in studying T-cell responses to viral infections.

The strategy addresses the Achilles heel of flu vaccines, which is to achieve specific antibody responses to different circulating influenza strains annually, by harnessing T-cell immunity against multiple strains. In particular, the new approach calls into action tissue-resident memory T-cells, or TRM cells, which reside in the airways and lining of lung epithelial cells and combat invading pathogens. Like elite soldiers, TRM cells serve as front line defense against infection.

Marulasiddappa Suresh

We didnt previously know how to elicit these tissue-resident memory cells with a safe protein vaccine, but we now have a strategy to stimulate them in the lungs that will protect against influenza, explains Suresh. As soon as a cell gets infected, these memory cells will kill the infected cells and the infection will be stopped in its tracks before it goes further.

Flu vaccines work by arming the immune system with an enhanced ability to recognize and fight off the flu virus. Vaccines introduce proteins found on the surface of flu viruses, prompting the immune system to produce antibodies that are primed to react should the virus attack.

However, because strains must be predicted ahead of flu season in order to produce vaccines, the vaccine in any given year may not completely match the viral strains in circulation that season. Flu viruses frequently mutate and can differ across time and from region to region. In addition, protection is neither long-lasting nor universal.

Even though current vaccines that people get annually stimulate antibody responses, these antibodies dont cross-protect, notes Suresh. If there is a new flu strain not found in that years vaccine, the antibodies that we generated last year wont be able to protect. Thats when pandemics happen because there is a completely new strain for which we have no antibodies. That is a really big problem in the field.

The vaccine developed by Suresh and his team is directed against an internal protein of influenza specifically, nucleoprotein. This protein is conserved between flu strains, meaning its genetic sequences are similar across different strains of flu.

The vaccine also utilizes a special combination of ingredients, or adjuvants, that enhance an immune response, which the researchers developed to stimulate protective T-cells in the lungs. These adjuvants spur T-cells to form into different subtypes in the case of the experimental flu vaccine, memory helper T-cells and killer T-cells. By doing so, the vaccine leverages multiple modes of immunity.

Killer T-cells hunt down and kill influenza virus-infected cells. Helper T-cells assist killer T-cells and produce molecules to promote influenza control. In laboratory studies, the team found that both T-cell types were needed to protect against flu.

Researchers demonstrated in a mouse model of influenza that the vaccine provides long-lasting immunity at least 400 days after vaccination against multiple flu strains. They will next test the vaccine in ferrets and nonhuman primates, two animal models of influenza research more biologically similar to human infection and transmission.

The vaccines combination of adjuvants makes it adaptable to other pathogens and expands the toolbox for vaccine research, notes Suresh. He and his team have devised ways to program immunity to target multiple respiratory viruses. They are currently testing the same vaccine strategy against tuberculosis, which infects more than 10 million people globally each year, and human respiratory syncytial virus, or RSV, a major cause of lower respiratory tract infections during infancy and childhood.

The researchers believe the same vaccine technology can applied against SARS-CoV-2, the coronavirus that causes COVID-19. Based on the COVID-19 immunology, we know this vaccine strategy would most likely work, says Suresh.

The team is now developing an experimental vaccine against COVID-19 and conducting laboratory tests to measure its effectiveness in mice and hamsters, animal models for COVID-19. Initial unpublished studies in mice show that the vaccine stimulates strong T-cell immunity against COVID-19 in the lungs.

Along with its adaptability, this vaccine approach may harbor important safety benefits. Typically, long-lasting T-cell immune responses are stimulated by live vaccines. For instance, the measles, mumps and chickenpox vaccines administered worldwide are live, replicating vaccines essentially benign versions of the pathogenic organism. These live vaccines stimulate strong, almost lifelong immunity. However, they cant typically be given to pregnant or immunocompromised individuals due to health risks.

In the case of the UWMadison teams vaccine, because it is a protein vaccine and not a live vaccine, it should be safe for delivery to those who are pregnant or immunocompromised an advantage in delivering protection to a wider patient population. Suresh says that in recent years, vaccine development efforts have shifted away from live vaccines toward protein vaccines because an increasing number of people are living with compromised immune systems due to chemotherapy, radiation treatments or conditions such as HIV/AIDS.

Previously, we didnt know how to induce T-cell immunity in the lung without live viruses, says Suresh. If we cleverly use a combination adjuvant, which we have developed, you can induce T-cell immunity that should stay in the lungs and protect longer.

THIS WORK WAS supported by THE NATIONAL INSTITUTES FOR HEALTH (GRANT UO1124299).

The rest is here:
New vaccine strategy harnesses 'foot soldier' T-cells to provide protection against influenza - University of Wisconsin-Madison

Vaxart Inc (VXRT) is around the top of the Biotechnology industry according to InvestorsObserver. VXRT received an overall rating of 81, which means that it scores higher than 81 percent of all stocks. Vaxart Inc also achieved a score of 93 in the Biotechnology industry, putting it above 93 percent of Biotechnology stocks. Biotechnology is ranked 23 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 81 would rank higher than 81 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Vaxart Inc (VXRT) stock has risen 8.5% while the S&P 500 is lower by -1.67% as of 11:41 AM on Monday, Sep 21. VXRT is up $0.70 from the previous closing price of $8.22 on volume of 23,715,904 shares. Over the past year the S&P 500 has gained 9.10% while VXRT is up 1615.38%. VXRT lost -$0.60 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Vaxart Inc (VXRT) Stock.

Follow this link:
Is Vaxart Inc (VXRT) The Right Choice in Biotechnology? - InvestorsObserver

Chicago, United States: The global Agricultural Biotechnology For Transgenic Crops Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Agricultural Biotechnology For Transgenic Crops Market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Agricultural Biotechnology For Transgenic Crops Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Agricultural Biotechnology For Transgenic Crops Market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Agricultural Biotechnology For Transgenic Crops Market.

Leading players of the global Agricultural Biotechnology For Transgenic Crops Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Agricultural Biotechnology For Transgenic Crops Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Agricultural Biotechnology For Transgenic Crops Market. It also provides useful recommendations for new as well as established players of the global Agricultural Biotechnology For Transgenic Crops Market.

Request for Sample Copy of This Report @https://www.reporthive.com/request_sample/2437198

Major Players:Monsanto, DowDuPont, Syngenta, BayerCropScience, Rubicon, Vilmorin, CertisUSA, Evogene, KWSSAAT, ADAMAAgriculturalSolutions, PerformancePlants, GlobalBio-chemTechnology

Segmentation by Product:

Artificial Genetically Modified (GM)Natural Genetically Modified (GM)

Segmentation by Application:

CornSoybeanCottonOthers

For Customised Template PDF Report:https://www.reporthive.com/request_customization/2437198

Scope of the Report:The all-encompassing research weighs up on various aspects including but not limited to important industry definition, product applications, and product types. The pro-active approach towards analysis of investment feasibility, significant return on investment, supply chain management, import and export status, consumption volume and end-use offers more value to the overall statistics on the Agricultural Biotechnology For Transgenic Crops Market. All factors that help business owners identify the next leg for growth are presented through self-explanatory resources such as charts, tables, and graphic images.

The insight has been added in the report to provide realistic overview of the industry, consist of Agricultural Biotechnology For Transgenic Cropsmanufacturers data, i.e. shipment, price, revenue, gross profit, business distribution, etc., SWOT analysis, consumer preference, recent developments and trends, drivers and restrain factors, company profile, investment opportunity, demand gap analysis, forecast market size value/volume, services and product, Porters Five Models, socioeconomic factors, government regulation in Agricultural Biotechnology For Transgenic Crops industry. Market players can use the report to peep into the future of the global Agricultural Biotechnology For Transgenic Crops Market and bring important changes to their operating style and marketing tactics to achieve sustained growth.

Global Agricultural Biotechnology For Transgenic Crops Market: Competitive RivalryThe chapter on company profiles studies the various companies operating in the global Agricultural Biotechnology For Transgenic Crops Market. It evaluates the financial outlooks of these companies, their research and development statuses, and their expansion strategies for the coming years. Analysts have also provided a detailed list of the strategic initiatives taken by the Agricultural Biotechnology For Transgenic Crops Market participants in the past few years to remain ahead of the competition.

Main Aspects covered in the Report->>Overview of the Agricultural Biotechnology For Transgenic Crops market including production, consumption, status & forecast and market growth->>2016-2020 historical data and 2021-2026 market forecast->>Geographical analysis including major countries->>Overview the product type market including development->>Overview the end-user market including development->>Impact of Coronavirus on the Industry

Table of Contents

Report Overview:It includes major players of the global Agricultural Biotechnology For Transgenic Crops Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Agricultural Biotechnology For Transgenic Crops Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Agricultural Biotechnology For Transgenic Crops Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Agricultural Biotechnology For Transgenic Crops Market by application, it gives a study on the consumption in the global Agricultural Biotechnology For Transgenic Crops Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Agricultural Biotechnology For Transgenic Crops Market are profiled in this section. The analysts have provided information about their recent developments in the global Agricultural Biotechnology For Transgenic Crops Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Agricultural Biotechnology For Transgenic Crops Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Agricultural Biotechnology For Transgenic Crops Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Agricultural Biotechnology For Transgenic Crops Market.

Key Findings: This section gives a quick look at important findings of the research study.

About Us:Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

Read the original post:
Global Covid-19 impact on Agricultural Biotechnology For Transgenic Crops Market: Business Opportunities, Current Trends And Industry Analysis By 2020...

When I was looking for universities to apply for an undergraduate programme, I heard about Rabindranath Tagore University (RNTU) and decided to visit the campus. I was astonished to see all the facilities offered here. Since the educational institutions in and around Vidisha dont offer similar facilities, I moved to Bhopal to join RNTU for a programme in Biotechnology.

This subject is used in different fields, including agriculture, environment and medicine and is slowly gaining popularity in India, especially in relation to agriculture, organic crops as well as cross breeding.

Infrastructure

At RNTU, we have access to excellent labs and equipment required for research, such as an in-house DNA fingerprinting lab and this makes the educational experience really engrossing.

Also, the teachers are supportive and helpful in creating an interactive learning experience. Presentations and audiovisual lessons and use of technology make the classes compelling.

The exposure to practical learning, as well as extracurricular activities, has improved my management and leadership skills. It has enabled me come out of my shell and explore the world as well as my own capabilities. One of my best experiences was representing my university at a national level debate competition organised by the Amity University, Lucknow.

In addition to participating in competitions, I was also a part of the volunteering committee at Vishwa Rang, the Tagore International Literature and Arts Festival during which I met and interacted with many artists and writers.

I was also a member of the organising team for the annual college festival Rhythm. We decided each act, divided the responsibilities and mapped of various activities with deadlines proper execution.

Even during the lockdown, we are constantly getting various internship opportunities so that our future is not adversely affected by the pandemic.

Kanika Soni is a third-year undergraduate student of Biotechnology from the Rabindranath Tagore University, Bhopal

You have reached your limit for free articles this month.

To get full access, please subscribe.

Already have an account ? Sign in

Show Less Plan

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Move smoothly between articles as our pages load instantly.

Enjoy reading as many articles as you wish without any limitations.

A one-stop-shop for seeing the latest updates, and managing your preferences.

A select list of articles that match your interests and tastes.

We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

View original post here:
Biotech and beyond - The Hindu

One of the biggest winners among coronavirus stocks in 2020 has been Vir Biotechnology(NASDAQ:VIR). The company's shares have more than doubled in the span of one year, turning a $10,000 investment from last September into about $22,700 today. That substantially outperformed the S&P 500, which gained 15% over the same period.

But sometimes, the higher you climb, the harder you fall. Recent controversy surrounding the company's progress with its COVID-19 programs caused the stock to fall more than 40% from its peak in late August. Should investors expect this company and its stock to rebound? Let's take a look at whether buying Vir on the dip is a golden opportunity or whether the company's drug pipeline spells trouble for its future.

Image Source: Getty Images.

Vir has two antibody treatments and a small interfering RNA (siRNA) treatment against COVID-19 in its pipeline. siRNA therapeutic candidates are based on tiny double-stranded RNA sequences coded to destroy genetic material responsible for a virus' protein synthesis, rendering it unable to replicate. The RNA treatment is undergoing preclinical studies, the results from which are expected by the end of the year. Meanwhile, one of the company's antibodies, VIR-7832, will enter phase 2 clinical trials in the fourth quarter, while the other, VIR-7831, is in phase 2/3 clinical trials. The latter candidate could made available first under an early access program like an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in the early months of 2021, if trial results are positive.

Vir has partnered with GlaxoSmithKline(NYSE:GSK) to develop its COVID-19 programs. The company is responsible for research and development (R&D) costs while GlaxoSmithKline is handling commercialization costs. Under the agreement, 72.5% of costs and profits go to Vir while the remaining 27.5% are GlaxoSmithKline's.

Without a doubt, Vir's pipeline has potential. However, there are already coronavirus treatments on the market, including Gilead Sciences'(NASDAQ:GILD) antiviral, remdesivir, and the generic steroid, dexamethasone. What's more, large-cap biotechs such as Moderna(NASDAQ:MRNA) andPfizer(NYSE:PFE) are already far along in their efforts to develop coronavirus vaccines. In fact, a vaccine could be available as soon as October. While there are no guarantees that any one of the vaccine candidates in particular will prove effective against COVID-19, it is likely that by 2022, the need for coronavirus treatments will have significantly diminished as people around the world are (hopefully) inoculated.

The company's hepatitis B pipeline is facing similar problems. Even though its treatment candidates for the disease are well into phase 2 trials, the question of their commercial feasibility is a key concern. There are already a number of effective hepatitis B vaccines available worldwide, meaning that the need for a treatment is limited to those who don't get immunized (or those whose immunizations are ineffective) and subsequently contract the virus. While 257 million people are currently living with hepatitis B, many are in developing nations and may not have the purchasing power to afford a pricey treatment course.

If that wasn't enough, Arrowhead Pharmaceuticals (NASDAQ:ARWR) andJohnson & Johnson (NYSE:JNJ) are also on their way to developing a treatment for hepatitis B. Clinical data for their candidate has looked solid. Whatever comes out of Vir's pipeline would have to compete with both existing standard-of-care treatments such as Entecavir and Tenofovir and new ones from other biotechs. This would significantly affect the company's pricing power in the event of its drug's approval.

Vir only brought in $67 million in combined licensing plus collaboration revenues in the past quarter. But currently, it has about $552.4 million in cash and investments, is operating at a net loss of $31.2 million per quarter, and has a $4.05 billion market cap. So in terms of its ability to keep moving forward with research and development, Vir's financial position is fair.

However, I don't think its shaky pipeline can justify its stock price, even after a recent decline. The market opportunities for hepatitis B and COVID-19 treatment candidates are too unstable and full of heavyweight pharma competitors. Buying Vir Biotechnology now could be like catching a falling knife. Investors looking at coronavirus stocks may wish to consider other opportunities.

Link:
Should You Buy Vir Biotechnology Stock on the Dip? - Motley Fool

- Corporate restructuring to extend cash runway through mid-2022 and key milestones -

- UBX1325 to enter clinical development in patients with diabetic macular edema -

SAN FRANCISCO, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it has initiated a restructuring to align its resources on cellular senescence programs in ophthalmology and neurology while further extending operating capital. UNITY will advance UBX1325 to Phase 1 clinical development in patients with diabetic macular edema, and expects to dose the first patient in the second half of 2020, consistent with prior guidance.

UNITY has prioritized its portfolio and aligned resources to deliver on key development milestones and drive innovation:

UBX1325 targets Bcl-xL, a novel mechanism to eliminate senescent cells in age-related diseases of the eye. The UBX1325 Phase 1 study in diabetic macular edema is expected to begin before the end of the year. UBX1967 remains in the portfolio as a molecularly distinct backup to UBX1325.

UNITYs neurology programs will target core features of neurodegenerative diseases. These programs build upon UNITYs foundational cellular senescence research platform and will focus on senolytic therapies for neurological diseases as well as exploring novel mechanisms for cognitive benefit.

UNITYs research programs will explore therapeutic modalities beyond small molecule approaches to significantly expand the target space for modulating senescent cell biology implicated as drivers of diseases of aging.

Revised Financial Guidance

UNITY will reduce its workforce by approximately 30% to optimize capital allocation and align with key strategic priorities, resulting in an estimated 75 full-time employees by the end of the year. These steps to focus resources are expected to extend the cash runway through mid-2022, with current cash and cash equivalents projected to fund UNITY through key clinical data readouts for UBX1325 and IND-enabling studies for UBX1967.

Story continues

"UNITY is a pioneer in the development of therapeutics targeting senescent cells at the crux of many age-related diseases, and we will continue to build on this scientific foundation as we advance our pipeline," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "At UNITY, we have an extraordinary team that has contributed greatly to the advancement of this field, and we are deeply grateful for the contributions that all of our employees have made. Moving forward we will have a leaner and more agile team, which is well-resourced to advance our pipeline programs to key milestones."

Dr. Ghosh added: We are excited about advancing UNITYs lead ophthalmology program, UBX1325, into clinical studies in patients with diabetic macular edema, an indication with a well-defined development path and objective endpoints. In addition, I see significant opportunities emerging from programs in our preclinical pipeline targeting ophthalmologic and neurologic disease. I look forward to using my experience leading drug discovery and development programs in these areas to advance the development of a new class of high efficacy therapies.

About UNITYUNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available atwww.unitybiotechnology.comor follow us onTwitter.

Forward-Looking Statements

This press release contains forward-looking statements including statements related to UNITYs understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to extend healthspan, including for ophthalmologic and neurologic disease, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for diabetic macular edema and other ophthalmological diseases, the expected timing of initial results of the Phase 1 study of UBX1325 in diabetic macular edema, the expected size of UNITYs workforce following the restructuring, the impact of the workforce reduction on UNITYs business, and UNITYs expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITYs most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed with the Securities and Exchange Commission on July 31, 2020, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.

Read the original here:
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology - Yahoo Finance

Latest Research Report: Piceatannol industry

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

Global Piceatannol Market documents a detailed study of different aspects of the Global Market. It shows the steady growth in market in spite of the fluctuations and changing market trends. The report is based on certain important parameters.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/148723

Piceatannol Market competition by top manufacturers as follow:Shaanxi Fuheng (FH) BiotechnologyXian Lyphar BiotechXian Finesky TechnologicalXa Bc-BiotechXian Huisun Bio-TechRiotto BotanicalXian Biof Bio-Technology

The risingtechnology in Piceatannolmarketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail. It includes a meticulous analysis of market trends, market shares and revenue growth patterns and the volume and value of the market. It is also based on a meticulously structured methodology. These methods help to analyze markets on the basis of thorough research and analysis.

The Type Coverage in the Market are: Industrial GradePharmaceutical Grade

Market Segment by Applications, covers:DrugsCosmeticsOthers

The research report summarizes companies from different industries. This Piceatannol Market report has been combined with a variety of market segments such as applications, end users and sales. Focus on existing market analysis and future innovation to provide better insight into your business. This study includes sophisticated technology for the market and diverse perspectives of various industry professionals.

Piceatannol is the arena of accounting worried with the summary, analysis and reporting of financial dealings pertaining to a business. This includes the training of financial statements available for public ingesting. The service involves brief, studying, checking and reporting of the financial contacts to tax collection activities and objects. It also involves checking and making financial declarations, scheming accounting systems, emerging finances and accounting advisory.

To get this report at a profitable rate.: https://reportsinsights.com/discount/148723

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Report Highlights: Detailed overview of parent market Changing market dynamics in the industry In-depth market segmentation Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape Strategies of key players and products offered Potential and niche segments, geographical regions exhibiting promising growth A neutral perspective on market performance Must-have information for market players to sustain and enhance their market footprint

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Piceatannol-Market-148723

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Originally posted here:
Piceatannol Market Incredible Possibilities, Growth Analysis and Forecast To 2025 | Shaanxi Fuheng (FH) Biotechnology, Xian Lyphar Biotech, Xian...

Plant Biotechnology Equipment Market Data and Acquisition Research Study with Trends and Opportunities 2019-2025The study of Plant Biotechnology Equipment market is a compilation of the market of Plant Biotechnology Equipment broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Plant Biotechnology Equipment industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Plant Biotechnology Equipment industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Request a sample of Plant Biotechnology Equipment Market report @ https://hongchunresearch.com/request-a-sample/60575

The following manufacturers are covered:Keygene(Netherlands)Heinz Walz GmbH (Germany)LemnaTec(Germany)Photon Systems Instruments(Czech Republic)Qubit Systems (Canada)Thermo Fisher Scientific (US)Tecan Group (Switzerland)LabRepCo (US)Geneq (Canada)Illumina (US)LGC Limited (UK)Evogene (Israel)

Access this report Plant Biotechnology Equipment Market @ https://hongchunresearch.com/report/worldwide-plant-biotechnology-equipment-market-2019-60575

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeSensors ModulesImaging DevicesAutomated SystemDronesLED LightingPortable Devices

Segment by ApplicationPlant ResearchBreedingProduct DevelopmentQuality AssessmentOthers

For a global outreach, the Plant Biotechnology Equipment study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitionsRevenue, cost price, capacity & utilizations, import/export rates and market shareForecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

To Check Discount of Plant Biotechnology Equipment Market @ https://hongchunresearch.com/check-discount/60575

Major Point of TOC:

Chapter One: Plant Biotechnology Equipment Market Overview

Chapter Two: Global Plant Biotechnology Equipment Market Competition by Manufacturers

Chapter Three: Global Plant Biotechnology Equipment Production Market Share by Regions

Chapter Four: Global Plant Biotechnology Equipment Consumption by Regions

Chapter Five: Global Plant Biotechnology Equipment Production, Revenue, Price Trend by Type

Chapter Six: Global Plant Biotechnology Equipment Market Analysis by Applications

Chapter Seven: Company Profiles and Key Figures in Plant Biotechnology Equipment Business

Chapter Eight: Plant Biotechnology Equipment Manufacturing Cost Analysis

Chapter Nine: Marketing Channel, Distributors and Customers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Plant Biotechnology Equipment Market Forecast

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Methodology and Data Source 13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Author List13.4 Disclaimer

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

Link:
Impact Of Covid-19 on Plant Biotechnology Equipment Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - The Daily...

Executive summary:

The latest report on Biotechnology Separation Systems market strives to provide a conclusive overview of the current and future market scenario with respect to the key growth catalysts, challenges, and opportunities across the various geographies.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/6449

The Biotechnology Separation Systems market is projected to expand with a CAGR of XX% during the forecast period 2020-2025.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/6449

In addition to region wise-assessment, the study also draws attention towards the competitive landscape by profiling the top contenders in the industry. A complete analysis of the various market segmentation is underlined in the report. Additionally, a detailed visualization of the global Covid-19 impact on the growth matrix of this business space is provided.

Market synopsis:

Regional outlook:

Product terrain outline:

Application spectrum overview:

Competitive landscape review:

Additional information from the Biotechnology Separation Systems market report:

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Market segmentation

The Biotechnology Separation Systems market is split by Type and by Application. For the period 2020-2025, the growth among segments provides accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Research Objective:

Why to Select This Report:

The research process begins with internal and external sources to obtain qualitative and quantitative information related to the Biotechnology Separation Systems market. It also provides an overview and forecast for the Biotechnology Separation Systems market based on all the segmentation provided for the global region. The predictions highlighted in the Biotechnology Separation Systems market share report have been derived using verified research procedures and assumptions. By doing so, the research report serves as a repository of analysis and information for every component of the Biotechnology Separation Systems market.

Request Customization on This Report @ https://www.theresearchprocess.com/request-for-customization/6449

Read the rest here:
Biotechnology Separation Systems Market Analysis, Revenue, Share, Growth Rate & Forecast To 2025 - The Research Process